Pregnancy, Ovarian
6
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Classical Antagonist Protocol
Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix
Clinical and Live Birth Rates After Following Long Antagonist Protocol Versus Long Agonist Protocol
The Number of Blastocysts Formed in the Outcome of Freeze All Strategy: COMFFETI Trial, Cumulative Delivery Rate
Genomic Imprinting and Assisted Reproductive Technologies
Biomarkers of Ovarian Reserve and Correlation With IVF Treatments